Two companies with different approaches to RNA medicines announced venture capital mega-rounds of $100m or more on 9 August – ADARx Pharmaceuticals, Inc. with a $200m series C financing and Alltrna with a $109m series B.
The month has had two other notable mega-round reveals, including a $105m crossover financing that CG Oncology, Inc. said it closed on 2 August. Kyverna Therapeutics also announced on 3 August that it closed a $60m series B extension, bringing the round’s total to $145m. These four financings may reestablish this year’s brisk mega-round pace, which slowed to just two $100m-plus VC rounds in July, including Kriya Therapeutics, Inc.’s $150m-plus series C extension